RecruitingNot Applicable

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

United States1,500 participantsStarted 2025-03-26

Plain-language summary

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU). * Signed a valid, IRB/EC-approved informed consent form. Exclusion Criteria: * Meets any contraindications per locally applicable Instructions for Use (IFU).

What they're measuring

Change in Disability (Oswestry Disability Index (ODI) from Baseline

Timeframe: 60-months post-procedure

Trial details

NCT IDNCT06827262

SponsorBoston Scientific Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2034-07

Contact for this trial

Ann Yamano

855-213-9890 BSNClinicalTrials@bsci.com

View on ClinicalTrials.gov More Chronic Low-back Pain trials